Neil Kumar - 29 Oct 2021 Form 3/A - Amendment Insider Report for LianBio (LIANY)

Role: Director
Signature: By: /s/ Angela Chen, Attorney-in-Fact
Issuer symbol: LIANY
Transactions as of: 29 Oct 2021
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 09 Nov 2021, 15:05:16 UTC
Date Of Original Report: 29 Oct 2021
Previous filing: 18 Aug 2021
Next filing: 18 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LIAN	Ordinary Shares						5,002,792	29 Oct 2021	By BridgeBio Pharma LLC	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney